Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin

被引：1
|
作者：
Sahin, Mustafa [1 ]
Miskioglu, Mine [2 ]
Inanir, Isil [3 ]
Akar, Hikmet [1 ]
Nese, Nalan [4 ]
Temiz, Peyker [4 ]
Aydogdu, Ismet [2 ]
机构：
[1] Celal Bayar Univ, Fac Med, Dept Internal Med, Manisa, Turkey
[2] Celal Bayar Univ, Fac Med, Dept Hematol, Manisa, Turkey
[3] Celal Bayar Univ, Fac Med, Dept Dermatol, Manisa, Turkey
[4] Celal Bayar Univ, Fac Med, Dept Patol, Manisa, Turkey
来源：
TURKISH JOURNAL OF HEMATOLOGY | 2021年 / 38卷 / 01期
关键词：
Cutaneous anaplastic large cell lymphoma; Brentuximab; Monotherapy; Breast cancer;
D O I：
10.4274/tjh.galenos.2020.2020.0512
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：85 / 87
页数：4
相关论文
共 50 条
  • [21] Complete Response of Relapsed Systemic and Cutaneous Anaplastic Large Cell Lymphoma Using Brentuximab Vedotin: 2 Case Reports
    Broccoli, Alessandro
    Derenzini, Enrico
    Pellegrini, Cinzia
    Narducci, Riccardo
    Stefani, Giulia
    Casadei, Beatrice
    Argnani, Lisa
    Zinzani, Pier Luigi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04): : 493 - 495
  • [22] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    Kenichi Ishizawa
    Tomoko Yanai
    Advances in Therapy, 2019, 36 : 2679 - 2696
  • [23] Primary Cutaneous Anaplastic Large-cell Lymphoma
    Perry, Edward
    Karajgikar, Jay
    Tabbara, Imad A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (05): : 526 - 529
  • [24] Primary Cutaneous Anaplastic Large-Cell Lymphoma
    Moodley, Nerissa
    Nombona, Patiswa
    Mosam, Anisa
    DERMATOPATHOLOGY, 2019, 6 (02): : 163 - 169
  • [25] Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma
    Calleja, Anne
    Bouclet, Florian
    BULLETIN DU CANCER, 2021, 108 (01) : 12 - 13
  • [26] Relapsed or refractory anaplastic large cell lymphoma: Brentuximab vedotin of course!
    Paillassa, Jerome
    HEMATOLOGIE, 2018, 24 (01): : 19 - 21
  • [27] Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients
    Monjanel, Helene
    Deville, Laure
    Ram-Wolff, Caroline
    Venon, Marie-Dominique
    Franchi, Patricia
    Benet, Claire
    de Kerviler, Eric
    Malphettes, Marion
    Thieblemont, Catherine
    Brice, Pauline
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (02) : 306 - +
  • [28] Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin
    Milan, Elisa
    Miceli, Paola
    Sernicola, Alvise
    Finotto, Silvia
    Marino, Dario
    Alaibac, Mauro
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (06)
  • [29] Brentuximab Vedotin in primary cutaneous CD30+large-cell anaplastic T-Cell Lymphoma
    Moritz, R. K. C.
    Patsinakidis, N.
    Terras, S.
    Moellenhoff, K.
    Gambichler, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 (09): : 921 - 921
  • [30] Brentuximab vedotin in multifocal cutaneous anaplastic large cell lymphoma in a patient with human immunodeficiency virus following Hodgkin lymphoma
    Wolf, S.
    Goiriz, R.
    Dhairyawan, R.
    Paige, D.
    Rizvi, H.
    Haroon, A.
    Montoto, S.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2019, 44 (05) : 562 - 564
12345